Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mazurier

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Thrombosis and Haemostasis|February 11, 2000
A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factorK Vanhoorelbeke, N Cauwenberghs, S Vauterin, et al.
Vox Sanguinis|January 1, 1987
In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factorC Mazurier, C de Romeuf, A Parquet-Gernez, et al.
American Journal of Hematology|July 1, 1986
Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtypeC Mazurier, P M Mannucci, A Parquet-Gernez, et al.
Thrombosis and Haemostasis|June 24, 1985
Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to plateletsJ Goudemand, C Mazurier, B Samor, et al.
Annales Francaises D'Anesthesie Et De Reanimation|January 1, 1986
[Course of plasma fibronectin in burn patients. Its variations during septic episodes]J P Galizia, M D Besse, C Mazurier, et al.
British Journal of Haematology|August 1, 1988
Investigation of a large kindred with type IIB von Willebrand's disease, dominant inheritance and age-dependent thrombocytopeniaC Mazurier, A Parquet-Gernez, J Goudemand, et al.
Best Practice & Research. Clinical Haematology|November 1, 2001
Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biologyC Mazurier, J Goudemand, L Hilbert, et al.
British Journal of Haematology|March 1, 1997
Rapid mutation screening in type 2A von Willebrand's disease using universal heteroduplex generatorsD Culpan, G Standen, N Wood, et al.
British Journal of Haematology|February 1, 1988
Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatmentJ Goudemand, B Samor, C Caron, et al.
The Journal of Biological Chemistry|October 15, 1992
Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparinA M Randi, S Jorieux, E A Tuley, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Thrombosis and Haemostasis|February 11, 2000
A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factorK Vanhoorelbeke, N Cauwenberghs, S Vauterin, et al.
Vox Sanguinis|January 1, 1987
In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factorC Mazurier, C de Romeuf, A Parquet-Gernez, et al.
American Journal of Hematology|July 1, 1986
Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtypeC Mazurier, P M Mannucci, A Parquet-Gernez, et al.
Thrombosis and Haemostasis|June 24, 1985
Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to plateletsJ Goudemand, C Mazurier, B Samor, et al.
Annales Francaises D'Anesthesie Et De Reanimation|January 1, 1986
[Course of plasma fibronectin in burn patients. Its variations during septic episodes]J P Galizia, M D Besse, C Mazurier, et al.
British Journal of Haematology|August 1, 1988
Investigation of a large kindred with type IIB von Willebrand's disease, dominant inheritance and age-dependent thrombocytopeniaC Mazurier, A Parquet-Gernez, J Goudemand, et al.
Best Practice & Research. Clinical Haematology|November 1, 2001
Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biologyC Mazurier, J Goudemand, L Hilbert, et al.
British Journal of Haematology|March 1, 1997
Rapid mutation screening in type 2A von Willebrand's disease using universal heteroduplex generatorsD Culpan, G Standen, N Wood, et al.
British Journal of Haematology|February 1, 1988
Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatmentJ Goudemand, B Samor, C Caron, et al.
The Journal of Biological Chemistry|October 15, 1992
Recombinant von Willebrand factor Arg578-->Gln. A type IIB von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparinA M Randi, S Jorieux, E A Tuley, et al.
Pageof 13